
Acta Neuropharmacologica››2011,Vol. 1››Issue (1): 26-31.
Previous ArticlesNext Articles
Nie Huizhen1, Wang Zejian1, Zhao Wenjuan1, Lu Jinmiao1, Zhang Can1, Luo Qinghe1, Wang Yuliang1, Gao Xiang2, Yin Ming1*
Online:2011-02-26Published:2011-10-20NIE Hui-Zhen, WANG Ze-Jian, ZHAO Wen-Juan, LU Jin-Miao, ZHANG Can, LUO Qing-He, WANG Yu-Liang, GAO Xiang, YIN Ming. Effects of nicotine analog ZY-1 on β-amyloid production and learning and memory in transgenic Alzheimer disease mice[J]. Acta Neuropharmacologica, 2011, 1(1): 26-31.
| 1. Cummings JL. Alzheimer’s disease[J]. N Engl J Med, 2004, 351(1):56-67 2. Zhu CW, Scarmeas N, Torgan R, et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease[J]. Neurology, 2006, 67(6):998-1005 3. Liu Q, Zhang J, Zhu H, et al. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model[J]. FASEB J, 2007; 21(1):61-73 4. Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease[J]. Curr Topics Med Chem, 2010, 10(2):144-152 5. Lippiello P, Letchworth SR, Gatto GJ, et al. Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties[J]. J Mol Neurosci, 2006, 30(1-2):19-20 6. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system[J]. Annu Rev Pharmacol Toxicol, 2007, 47:699-729 7. Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology[J]. Ann N Y Acad Sci, 2003, 998:41-52 8. Qi XL, Nordberg A, Xiu J, et al. The consequences of reducing expression of the alpha 7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha 7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease[J]. Neurochem. Int., 2007, 51(6-7), 377-383 9. Chan WK, Wong PT, Sheu FS, et al. Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory[J]. Neuropharmacology. 2007, 52(8):1641-9 10. Dineley KT. Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: the two faces of health and disease[J]. Front Biosci, 2007, 12:5030-5038 11. Meunier J, Ieni J, Maurice T, et al. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25–35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor[J]. Br J Pharmacol, 2006, 149(8):998-1012 12. Vasto S, Candore G, Aquino A, et al. The nAChR4 594C/T polymorphism in Alzheimer disease[J]. Rejuvenation Res, 2006, 9(1):107-110 13. Lai MK, Tsant SW, Garci-Alloza M, et al. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer’s disease[J]. Neurobiol Dis, 2006, 22(3):555-561 14. Sabri O, Kenzziorra K, Wolf H, et al. Acetylcholine receptors in dementia and mild cognitive impairment[J]. Eur J Nucl Med Mol Imaging. 2008, 35 Suppl 1:S30-45 15. Sabbagh MN, Shah F, Reid RT, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging[J]. Arch Neurol, 2006, 63(12):1771-1776 16. Hernandez CM, Kayed R, Zheng H, et al. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease[J]. J Neurosci. 2010, 17;30(7):2442-2453 17. Akaike A, Takada-Takatori Y, Kume T, et al., Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection[J]. J Mol Neurosci. 2010, 40(1-2):211-216 18. Arneric SP, Holladay M, Williams M, et al. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research[J]. Biochem Pharmacol, 2007, 74(8):1092-1101 19. Sabey K, Paradiso K, Zhang J, et al. Ligand binding and activation of rat nicotinic α4β2 receptors stably expressed in HEK293 cells[J]. Mol Pharmacol, 1999, 55(1):58–66 |
| [1] | DU Jia-rui, LIU Fu-wang, SHEN Xu-ri, et al.Evaluation of APP/PS-1/Tau Female Mice to Simulate the Pathological Model of Female AD[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(5): 1-. |
| [2] | ZHU Chao,DU Ning-ning,ZHOU Yan-meng,WANG Hao,HOU Xue-qin,ZHANG Fang-fang,TAN Rui,GAO.Increased Blood Pressure Variability Impairs Memory in Rats[J]. Acta Neuropharmacologica, 2018, 8(5): 79-80. |
| [3] | Liu Min, Guo Hai-biao, Li Chu-yuan, Wang De-qin, Xu Jiang-ping, Qin Ren-an.Study on the Effect and Mechanism of Early Intervention with Compound Danshen Tablet on Learning and Memory in APP/PS1 Transgenic Mice[J]. Acta Neuropharmacologica, 2014, 4(5): 1-7. |
| [4] | LI Ying-jie,YANG Bao-xue.Anesthetic Mechanism, Its Protective Effect and Ion Channels[J]. Acta Neuropharmacologica, 2013, 3(4): 39-46. |
| [5] | LIU Hong-bin,WU Hai-xia.Overview of the Pathogenesis and Animal Models of Alzheimer's Disease[J]. Acta Neuropharmacologica, 2013, 3(4): 14-22. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||